Quantcast

Latest tumor Stories

2014-05-01 08:35:09

Preliminary Observations Presented at GEST Show Increased Tumor Penetration with the Surefire SAN FRANCISCO, May 1, 2014 /PRNewswire/ -- Surefire Medical, Inc. announced today that early observations from the first direct comparison of the Surefire Infusion System vs. a standard end hole catheter in vivo will be presented at the Global Embolization Symposium and Technologies (GEST) meeting in San Francisco May 1-4. The University of Tennessee Medical Center prospective study uses...

2014-04-29 08:35:53

Presentation at the American Association for Thoracic Surgery 94th Annual Meeting TORONTO, April 29, 2014 /PRNewswire/ -- Castle Biosciences Inc. announced that data from two validation studies of its DecisionDx-Mesothelioma molecular test were presented at the American Association for Thoracic Surgery 94(th) Annual Meeting. According to the data, the test accurately predicted survival in metastatic pleural mesothelioma (MPM) patients based on the gene expression profile signature...

2014-04-23 08:31:41

- Investigators to Present Clinical Trial Findings Evaluating Compounds in Multiple Tumor Types NORTH CHICAGO, Ill., April 23, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data evaluating a number of investigational compounds in the company's oncology pipeline will be presented at the upcoming 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 - June 3, in Chicago. "Our clinical trial program underscores our commitment to developing innovative...

2014-04-16 14:11:59

A University of Texas at Arlington physicist working to create a luminescent nanoparticle to use in security-related radiation detection may have instead happened upon an advance in photodynamic cancer therapy. Wei Chen, professor of physics and co-director of UT Arlington's Center for Security Advances Via Applied Nanotechnology, was testing a copper-cysteamine complex created in his lab when he discovered unexplained decreases in its luminescence, or light emitting power, over a...

2014-04-16 12:30:22

Advanced Tumor Modeling for Evaluation of Cancer Therapy Efficacy at the Cellular Level MENLO PARK, Calif., April 16, 2014 /PRNewswire/ -- SRI International has announced the availability of its PDCellX(TM) xenograft tumor model services for testing the activity of potential cancer therapeutics. PDCellX models provide clinically relevant information that allows researchers to evaluate the efficacy of cancer drug candidates in new models that go beyond traditional tumor xenograft...

2014-04-13 23:00:43

Transparency Market Research Report Added "Anti-Tumor Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" to its database. Browse Full Report: http://www.transparencymarketresearch.com/anti-tumor-drugs-market.html. Albany, New York, USA (PRWEB) April 13, 2014 Tumor is also termed as neoplasm and it is caused by an abnormal proliferation of tissues. This abnormal proliferation can be due to genetic mutations. Tumors can be...

2014-04-11 12:07:26

A group of researchers in China and the US have successfully created a 3D model of a cancerous tumor using a 3D printer. The model, which consists of a scaffold of fibrous proteins coated in cervical cancer cells, has provided a realistic 3D representation of a tumor's environment and could help in the discovery of new drugs and cast new light on how tumors develop, grow and spread throughout the body. The results of the study have been published today, 11 April, in IOP Publishing's...

2014-04-09 16:37:59

The findings shed more light on cancer development and metastasis. The push and pull of physical force can cause profound changes in the behavior of a cell. Two studies from researchers working at the UNC Lineberger Comprehensive Cancer Center reveal how cells respond to mechanical manipulation, a key factor in addressing the underlying causes of cancer and other diseases. The studies, published in Nature Cell Biology and the Journal of Immunology, have their roots in a longtime...

2014-04-09 12:31:10

VAL-083 therapy is well tolerated to date; dose limiting toxicity has not been reached after fifth cohort (20mg/m2) VANCOUVER, British Columbia and MENLO PARK, Calif., April 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced an update on its ongoing Phase I/II clinical trial with VAL-083 in the treatment of refractory glioblastoma multiforme (GBM). The company's new data are being presented in a poster entitled, "A Phase I/II Study of VAL-083 in...

2014-04-08 10:43:57

The difference between an immune response that kills cancer cells and one that conversely stimulates tumor growth can be as narrow as a "double-edged sword," report researchers at the University of California, San Diego School of Medicine in the April 7, 2014 online issue of the Proceedings of the National Academy of Sciences. "We have found that the intensity difference between an immune response that stimulates cancer and one that kills it may not be very much," said principal...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related